|
gptkbp:instance_of
|
gptkb:depression
|
|
gptkbp:approves
|
2010 in the USA
2011 in the EU
|
|
gptkbp:atccode
|
N05 AX
|
|
gptkbp:brand
|
gptkb:Invega_Sustenna
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
acute treatment
maintenance treatment
monthly injection
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to paliperidone
|
|
gptkbp:dosage_form
|
suspension
|
|
gptkbp:effective_date
|
gptkb:2010
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
long-acting injectable
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xeplion
|
|
gptkbp:indication
|
bipolar disorder
schizoaffective disorder
|
|
gptkbp:ingredients
|
gptkb:paliperidone
|
|
gptkbp:legal_status
|
prescription only
|
|
gptkbp:lifespan
|
approximately 30 hours
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Invega_Sustenna
gptkb:Invega_Trinza
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
pre-filled syringe
|
|
gptkbp:patient_population
|
adults
adolescents
|
|
gptkbp:pharmacokinetics
|
dopamine receptor antagonist
serotonin receptor antagonist
linear pharmacokinetics
dose proportionality
|
|
gptkbp:provides_guidance_on
|
gptkb:National_Institute_for_Health_and_Care_Excellence
gptkb:American_Psychiatric_Association
|
|
gptkbp:related_products
|
gptkb:Risperidone
gptkb:Invega
Paliperidone palmitate
|
|
gptkbp:research_areas
|
mental health
neuroscience
psychiatry
|
|
gptkbp:route_of_administration
|
intramuscular injection
|
|
gptkbp:side_effect
|
seizures
drowsiness
weight gain
increased cholesterol
hyperglycemia
thromboembolism
extrapyramidal symptoms
QT prolongation
neuroleptic malignant syndrome
tardive dyskinesia
|
|
gptkbp:storage
|
store in a refrigerator
|
|
gptkbp:structure
|
C23 H29 N3 O3 S
|
|
gptkbp:used_for
|
treatment of schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:Invega_Sustenna
|
|
gptkbp:bfsLayer
|
7
|